Study of Efficacy of CDZ173 in Patients With APDS/PASLI
NCT02435173
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
DRUG:
CDZ173
OTHER:
Placebo
Sponsor
Novartis Pharmaceuticals